TaiMed Biologics Inc’s (中裕新藥) sales of its Trogarzo HIV treatment are forecast to boom this year after the European Commission on Thursday last week approved it to be marketed, the company said yesterday.
The company plans to begin marketing the drug in Germany this year, as the nation has friendly regulations on drug pricing, allowing companies to market products before wholesale prices are finalized, TaiMed chief financial officer Jack Chen (陳怡成) said by telephone.
Company partner Montreal-based Theratechnologies Inc has begun making connections with hospitals and patients in Germany, targeting sales of the drug by the end of this year or at the beginning of next year, Chen said.
Theratechnologies — TaiMed’s exclusive marketing and distribution partner in more than 30 markets, including the US, Canada and the EU — is to negotiate prices with regulatory bodies in Europe, he said.
The European price has been estimated at 30 percent lower than US$118,000 for a year of treatment in the US, he said.
Trogarzo is a fourth-line treatment and a drug that is designed for people with multi-drug resistance, TaiMed said.
The number of people in Europe with HIV/AIDS who are multi-drug resistant, which means they require alternative treatments, is estimated to be between 20,000 and 25,000, Chen said.
TaiMed is to pay US$5 million to US-based Genentech Inc as a milestone payment, as Genentech developed and licensed the antibody ibalizumab (TMB-355), a key ingredient of Trogarzo.
TaiMed posted revenue of NT$283 million (US$9.12 million) in the first half of this year and expects its full-year revenue to reach NT$800 million thanks to stable sales of Trogarzo in the US, Chen said, adding that the company started marketing the drug in the US in April last year.
It reported a non-operating loss of NT$43 million in the first half, due to a drop in the value of its stake in Theratechnologies, Chen said.
Gross margin fell to 17 percent for the first six months due to low production yield at contract manufacturer WuXi Biologics Co (無錫生物製藥), which is responsible for the production of Trogarzo, Chen said, adding that the yield improved in the third quarter.
CHIP RACE: Three years of overbroad export controls drove foreign competitors to pursue their own AI chips, and ‘cost US taxpayers billions of dollars,’ Nvidia said China has figured out the US strategy for allowing it to buy Nvidia Corp’s H200s and is rejecting the artificial intelligence (AI) chip in favor of domestically developed semiconductors, White House AI adviser David Sacks said, citing news reports. US President Donald Trump on Monday said that he would allow shipments of Nvidia’s H200 chips to China, part of an administration effort backed by Sacks to challenge Chinese tech champions such as Huawei Technologies Co (華為) by bringing US competition to their home market. On Friday, Sacks signaled that he was uncertain about whether that approach would work. “They’re rejecting our chips,” Sacks
It is challenging to build infrastructure in much of Europe. Constrained budgets and polarized politics tend to undermine long-term projects, forcing officials to react to emergencies rather than plan for the future. Not in Austria. Today, the country is to officially open its Koralmbahn tunnel, the 5.9 billion euro (US$6.9 billion) centerpiece of a groundbreaking new railway that will eventually run from Poland’s Baltic coast to the Adriatic Sea, transforming travel within Austria and positioning the Alpine nation at the forefront of logistics in Europe. “It is Austria’s biggest socio-economic experiment in over a century,” said Eric Kirschner, an economist at Graz-based Joanneum
BUBBLE? Only a handful of companies are seeing rapid revenue growth and higher valuations, and it is not enough to call the AI trend a transformation, an analyst said Artificial intelligence (AI) is entering a more challenging phase next year as companies move beyond experimentation and begin demanding clear financial returns from a technology that has delivered big gains to only a small group of early adopters, PricewaterhouseCoopers (PwC) Taiwan said yesterday. Most organizations have been able to justify AI investments through cost recovery or modest efficiency gains, but few have achieved meaningful revenue growth or long-term competitive advantage, the consultancy said in its 2026 AI Business Predictions report. This growing performance gap is forcing executives to reconsider how AI is deployed across their organizations, it said. “Many companies
France is developing domestic production of electric vehicle (EV) batteries with an eye on industrial independence, but Asian experts are proving key in launching operations. In the Verkor factory outside the northern city of Dunkirk, which was inaugurated on Thursday, foreign specialists, notably from South Korea and Malaysia, are training the local staff. Verkor is the third battery gigafactory to open in northern France in a region that has become known as “Battery Valley.” At the Automotive Energy Supply Corp (AESC) factory near the city of Douai, where production has been under way for several months, Chinese engineers and technicians supervise French recruits. “They
RSS